Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts

Pier D. Lambiase*, Michael R. Gold, Margaret Hood, Lucas Boersma, Dominic A.M.J. Theuns, Martin C. Burke, Raul Weiss, Andrea M. Russo, Stefan Kääb, Bradley P. Knight

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

94 Scopus citations

Abstract

Background The subcutaneous implantable cardioverter-defibrillator (S-ICD) is a potential alternative to transvenous systems in hypertrophic cardiomyopathy (HCM) where lead complications are a significant issue. Objectives To compare the S-ICD efficacy of defibrillation threshold (DFT) testing, arrhythmia therapy, and complications in HCM versus non-HCM patients. Methods Outcomes of patients with HCM implanted with S-ICD were compared to non-HCM S-ICD recipients using pooled data from a total of 872 subjects enrolled in the EFFORTLESS Registry and US IDE study. Results The cohort included 99 HCM (75% male) and 773 non-HCM (72% male) patients with a median follow-up of 637 days. The HCM cohort was younger and more likely to receive a primary-prevention S-ICD (88.5% vs 67.5%, P <.0001). During implant testing, successful defibrillation at ≤80 J was achieved in 98.9% of HCM and 98.5% of non-HCM patients. One year postoperative complication-free rates were similar: 92.7% in HCM (with no lead complications) versus 89.5% in non-HCM. There were 3 appropriate shocks for ventricular tachycardia in 3 HCM patients that were all converted by the first shock. Overall final shock conversion efficacy was 100% in HCM versus 98% in non-HCM (P = ns). Inappropriate shocks occurred in 12.5% of HCM patients and 10.3% of non-HCM patients (P = ns), being reduced by 47% using dual-zone programming. Conclusion These initial data indicate the S-ICD is safe and effective in patients with HCM who are at high risk of ventricular arrhythmias and pass preimplantation electrocardiogram screening. Inappropriate shocks were mainly due to T-wave oversensing, but there were no lead complications requiring reintervention.

Original languageEnglish (US)
Pages (from-to)1066-1074
Number of pages9
JournalHeart rhythm
Volume13
Issue number5
DOIs
StatePublished - May 1 2016

Funding

Disclosures: Dr Burke: consultant, advisory boards, and research grants from Boston Scientific; Dr Gold: grants and personal fees from Boston Scientific, outside the submitted work; Dr Knight: grants from Boston Scientific/Cameron Health, during the conduct of the study; personal fees from Boston Scientific, outside the submitted work; Dr Lambiase: research grants from Boston Scientific, St Jude, Medtronic, during the conduct of the study; Dr Russo: grants and advisory board from Boston Scientific, during the conduct of the study; other from Boston Scientific, outside the submitted work; Dr Theuns: grants from Boston Scientific, during the conduct of the study; personal fees from Boston Scientific, outside the submitted work; Dr Weiss: other from Cameron Health/Boston Scientific (fees received by Ohio State University), during the conduct of the study; grants from St Jude, grants from Medtronic, grants from Biotronik, outside the submitted work.

Keywords

  • Hypertrophic cardiomyopathy
  • Subcutaneous ICD
  • Ventricular arrhythmias

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Fingerprint

Dive into the research topics of 'Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts'. Together they form a unique fingerprint.

Cite this